Category Reports Biotech

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Phase 3 clinical-stage pharmaceutical company dedicated to developing innovative therapies for hard-to-treat tumors and viruses. The company's lead candidate, Annamycin, is advancing in the pivotal Phase 3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (AML), with the first unblinding of data anticipated in Q1 2026.

Serina Therapeutics is a clinical-stage biotechnology company based in Huntsville, Alabama, built around its proprietary POZ Platform, a drug optimization technology based on a controlled, water-soluble poly(2-oxazoline) polymer. The platform is designed to tune half-life, exposure and tissue distribution of small molecules, peptides and biologics, with the ambition of generating “best-in-class” dosing profiles versus conventional formulations.

FDA asks for the full HOPE-3 clinical study report but does not require new trials, while Capricor prepares a February BLA update. The stock hovers around 23–24 $, with a market cap near 1.16 B$, after a 2025 rally fuelled by Duchenne data and aggressive retail positioning.

FDA places a clinical hold on RGX-111 (MPS I) and RGX-121 (MPS II) programs after a single intraventricular CNS tumor in an RGX-111 patient.
Preliminary analysis shows an AAV vector integration event near proto-oncogene PLAG1; causality is still under investigation.
NAVSUNLI (RGX-121) BLA for MPS II remains under priority review with a PDUFA date of February 8, 2026; no public change to that date has been announced as of this report.

As of January 27, 2026, Cardiff Oncology (NASDAQ: CRDF) is trading around 2 dollars per share after a single-session loss of roughly thirty-two percent. The trigger was a GlobeNewswire press release announcing that long-time Chief Executive Officer Mark Erlander and Chief Financial Officer James Levine are both stepping down, with board member Mani Mohindru becoming interim CEO and Senior Vice President of Finance Brigitte Lindsay moving up as interim CFO.

COYA Therapeutics Holdings represents a high-risk opportunity in the biotech sector, focused on developing innovative therapies for neurodegenerative and autoimmune diseases through regulatory T-cell (Treg) modulation. With a pipeline including candidates for ALS, Alzheimer's, and other complex pathologies, the company positions itself in a therapeutic area with significant unmet medical needs but also with high clinical failure rates.

Kura Oncology is a precision oncology company built around one central thesis: targeting oncogenic signalling nodes such as menin and farnesyl transferase can reset the biology of hard-to-treat cancers, especially acute myeloid leukemia (AML).

Celcuity (CELC) – Gedatolisib PDUFA July 17, 2026: Setup, Risks and RunUP Map | Merlintrader trading Blog English Italiano Celcuity (CELC) – Gedatolisib PDUFA July 17, 2026 PI3K/mTOR inhibitor in HR+/HER2- metastatic breast cancer – binary PDUFA, cash runway and…

RGX-121 puts Regenxbio at the threshold of its first potential standalone approval, while the retina (AbbVie) and Duchenne programs build a second and third pillar for 2026–2027. The equity story is a classic “platform + royalty + binary PDUFA” mix, with a balance sheet extended into early 2027 via upfronts and royalty monetization.

Cadrenal Therapeutics (NASDAQ: CVKD) is a clinical-stage biopharma headquartered in Ponte Vedra, Florida, focused on anticoagulation solutions for high-risk patients who are poorly served by current therapies. The company was formed in 2022 around tecarfarin and, through two 2025 acquisitions, has expanded into a broader platform combining VKA, Factor XIa and 12-LOX mechanisms.

After years of being “just a pipeline story”, Eton has transitioned into a small but diversified rare-disease platform with multiple approved assets and a focused late-stage pipeline anchored by ET-400 and ET-600.